Broncho-Vaxom is under clinical development by OM Pharma and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I drugs for Allergic Asthma have a 78% phase transition success ...
Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...
Research using nasal swabs to identify asthma subtypes promises precise treatment. T2-high asthma may be less common than T2-low, suggesting a need for new treatments. Meanwhile, insights into why ...
Too little attention is paid to the connection between the two diseases. According to a recent survey commissioned by the Austrian Lung Union (ÖLU), ...